Sintilimab blood levels in advanced stomach cancer
Part of Cancer, Digestive system clinical trials.
This study looks at how the amount of Sintilimab in your blood relates to how well it works and what side effects you might have. If you have advanced stomach cancer and are planning to get Sintilimab, this trial could help your doctor find the best dose for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with adenocarcinoma of the stomach or where the stomach meets the esophagus.
- You plan to receive treatment with the drug Sintilimab (a type of immunotherapy).
- Your current health status allows you to be up and active at least half the day (ECOG score 0 to 2).
- Your doctor expects you to live at least 3 more months.
- You are willing and able to follow the treatment plan and come to appointments.
- You agree to join the study and sign a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an immunotherapy drug (sintilimab) and two chemotherapy drugs (nab-paclitaxel and tegafur) as a first treatment for stomach or gastroesophageal junction cancer that cannot be removed by surgery or has spread. The goal is to see if this combination helps people live longer and controls the cancer better.
This trial tests whether adding the immunotherapy drug sintilimab to standard chemoradiotherapy can help people aged 75 or older with locally advanced stomach cancer. It aims to shrink tumors and improve outcomes.
This trial tests combining an immunotherapy drug (sintilimab) with a targeted therapy (ramucirumab) and chemotherapy (paclitaxel) for stomach cancer that came back soon after surgery and chemotherapy. The goal is to see if this combined approach can help control the cancer and prolong life.
This trial tests whether adding an immunotherapy drug called sintilimab to chemotherapy and radiation before surgery can help shrink tumors and improve outcomes for people with gastroesophageal junction cancer. It is designed for patients who have not had previous treatment for this cancer.
This trial tests whether adding the immunotherapy drug sintilimab to standard chemotherapy (SOX) after surgery helps prevent stomach cancer from returning. It’s for people whose tumors have a protein called PD-L1 and who had cancer in at least 7 lymph nodes.
This trial tests whether the immunotherapy drug Sintilimab can help prevent esophageal cancer from returning after standard chemotherapy and radiation. It is for patients aged 70-85 who cannot have or choose not to have surgery.
Hear when a new Gastric (Cardia, Body) Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.